4/A: Pasithea Therapeutics CFO Corrects Stock Option Exercise Price in Amended SEC Filing

Daniel Schneiderman, CFO of Pasithea Therapeutics, files an amended Form 4 to correct the exercise price of stock options granted on March 1, 2024.

Summary

• Daniel H Schneiderman, Chief Financial Officer of Pasithea Therapeutics Corp. (KTTA), filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price of stock options granted on March 1, 2024.
• The original filing erroneously reported the exercise price as $8.34 per share.
• The corrected exercise price is $8.13 per share, based on the closing price of KTTA common stock on March 1, 2024.
• Schneiderman was granted two stock option awards on March 1, 2024: one for 10,000 shares and another for 5,927 shares.
• The 10,000 share option vests over three years, with 33% vesting after one year and the remainder in equal quarterly installments.
• The 5,927 share option was fully vested upon issuance and became exercisable on March 1, 2024.
• The filing also notes a 1-for-20 reverse stock split that occurred on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company, but accuracy in reporting is viewed positively.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders benefit from accurate reporting of insider transactions.

Key Dates

Keywords

Form 4, Pasithea Therapeutics, Stock Options, Daniel Schneiderman, CFO, KTTA, Reverse Stock Split, SEC Filing